Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma

C. H N Veenhof, M. E L van der Burg, M. Nooy, J. G. Aalders, S. Pecorelli, C. F. Oliveira, N. Rotmensz, J. B. Vermorken

Research output: Contribution to journalArticle

Abstract

The EORTC Gynaecological Cancer Cooperative Group conducted a phase II study of high dose oral megestrol acetate: 800 mg/day for 1 month followed by 400 mg/day as maintenance treatment, in heavily pretreated patients with ovarian cancer. Of 72 patients included in this study, 54 were fully evaluable for response and toxicity. The response rate was low with only 1 patient having a partial reponse, 9 patients with stable disease and 44 patients with progressive disease. The toxicity profile was low. However, 1 patient died after 2 months of treatment, and in 3 patients thrombo-embolic events occurred. Weight gain varied in 20 of the 61 patients from 0.5 to 16 kg. This study does not suggest that the overall 10% benefit from hormonal therapy for chemotherapy refractory ovarian cancer will improve by increasing the dose.

Original languageEnglish
Pages (from-to)697-698
Number of pages2
JournalEuropean Journal of Cancer
Volume30
Issue number5
DOIs
Publication statusPublished - 1994

Fingerprint

Megestrol Acetate
Carcinoma
Ovarian Neoplasms
Weight Gain
Therapeutics
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Veenhof, C. H. N., van der Burg, M. E. L., Nooy, M., Aalders, J. G., Pecorelli, S., Oliveira, C. F., ... Vermorken, J. B. (1994). Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. European Journal of Cancer, 30(5), 697-698. https://doi.org/10.1016/0959-8049(94)90548-7

Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. / Veenhof, C. H N; van der Burg, M. E L; Nooy, M.; Aalders, J. G.; Pecorelli, S.; Oliveira, C. F.; Rotmensz, N.; Vermorken, J. B.

In: European Journal of Cancer, Vol. 30, No. 5, 1994, p. 697-698.

Research output: Contribution to journalArticle

Veenhof, CHN, van der Burg, MEL, Nooy, M, Aalders, JG, Pecorelli, S, Oliveira, CF, Rotmensz, N & Vermorken, JB 1994, 'Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma', European Journal of Cancer, vol. 30, no. 5, pp. 697-698. https://doi.org/10.1016/0959-8049(94)90548-7
Veenhof CHN, van der Burg MEL, Nooy M, Aalders JG, Pecorelli S, Oliveira CF et al. Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. European Journal of Cancer. 1994;30(5):697-698. https://doi.org/10.1016/0959-8049(94)90548-7
Veenhof, C. H N ; van der Burg, M. E L ; Nooy, M. ; Aalders, J. G. ; Pecorelli, S. ; Oliveira, C. F. ; Rotmensz, N. ; Vermorken, J. B. / Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. In: European Journal of Cancer. 1994 ; Vol. 30, No. 5. pp. 697-698.
@article{fe648c16edec4c13b94e3851e19de16b,
title = "Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma",
abstract = "The EORTC Gynaecological Cancer Cooperative Group conducted a phase II study of high dose oral megestrol acetate: 800 mg/day for 1 month followed by 400 mg/day as maintenance treatment, in heavily pretreated patients with ovarian cancer. Of 72 patients included in this study, 54 were fully evaluable for response and toxicity. The response rate was low with only 1 patient having a partial reponse, 9 patients with stable disease and 44 patients with progressive disease. The toxicity profile was low. However, 1 patient died after 2 months of treatment, and in 3 patients thrombo-embolic events occurred. Weight gain varied in 20 of the 61 patients from 0.5 to 16 kg. This study does not suggest that the overall 10{\%} benefit from hormonal therapy for chemotherapy refractory ovarian cancer will improve by increasing the dose.",
author = "Veenhof, {C. H N} and {van der Burg}, {M. E L} and M. Nooy and Aalders, {J. G.} and S. Pecorelli and Oliveira, {C. F.} and N. Rotmensz and Vermorken, {J. B.}",
year = "1994",
doi = "10.1016/0959-8049(94)90548-7",
language = "English",
volume = "30",
pages = "697--698",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "5",

}

TY - JOUR

T1 - Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma

AU - Veenhof, C. H N

AU - van der Burg, M. E L

AU - Nooy, M.

AU - Aalders, J. G.

AU - Pecorelli, S.

AU - Oliveira, C. F.

AU - Rotmensz, N.

AU - Vermorken, J. B.

PY - 1994

Y1 - 1994

N2 - The EORTC Gynaecological Cancer Cooperative Group conducted a phase II study of high dose oral megestrol acetate: 800 mg/day for 1 month followed by 400 mg/day as maintenance treatment, in heavily pretreated patients with ovarian cancer. Of 72 patients included in this study, 54 were fully evaluable for response and toxicity. The response rate was low with only 1 patient having a partial reponse, 9 patients with stable disease and 44 patients with progressive disease. The toxicity profile was low. However, 1 patient died after 2 months of treatment, and in 3 patients thrombo-embolic events occurred. Weight gain varied in 20 of the 61 patients from 0.5 to 16 kg. This study does not suggest that the overall 10% benefit from hormonal therapy for chemotherapy refractory ovarian cancer will improve by increasing the dose.

AB - The EORTC Gynaecological Cancer Cooperative Group conducted a phase II study of high dose oral megestrol acetate: 800 mg/day for 1 month followed by 400 mg/day as maintenance treatment, in heavily pretreated patients with ovarian cancer. Of 72 patients included in this study, 54 were fully evaluable for response and toxicity. The response rate was low with only 1 patient having a partial reponse, 9 patients with stable disease and 44 patients with progressive disease. The toxicity profile was low. However, 1 patient died after 2 months of treatment, and in 3 patients thrombo-embolic events occurred. Weight gain varied in 20 of the 61 patients from 0.5 to 16 kg. This study does not suggest that the overall 10% benefit from hormonal therapy for chemotherapy refractory ovarian cancer will improve by increasing the dose.

UR - http://www.scopus.com/inward/record.url?scp=0028337478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028337478&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(94)90548-7

DO - 10.1016/0959-8049(94)90548-7

M3 - Article

C2 - 8080689

AN - SCOPUS:0028337478

VL - 30

SP - 697

EP - 698

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 5

ER -